Business
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoart
About this update from Anika Therapeutics Inc.
[{"type":"image","alt":"Anika Therapeutics Inc.","displaySize":"","headline":null,"caption":"Anika Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/87f8d0b1520f9e5cf005c5f7008d1e8b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hCNw0eG2QbR25b1UHhgLww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/87f8d0b1520f9e5cf005c5f7008d1e8b","width":300,"height":157}},"lazy":false},{"type":"text","content":"Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target","length":109,"tagName":"p"},{"type":"text","content":"Commercial Channel grew 22% and 15% for Q4 and full year, respectively","length":70,"tagName":"p"},{"type":"text","content":"Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year","length":96,"tagName":"p"},{"type":"text","content":"FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission ","length":99,"tagName":"p"},{"type":"text","content":"BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 31, 2025.","length":324,"tagName":"p"},{"type":"text","content":"Anika reported fourth quarter revenue of $30.6 million, flat compared to the fourth quarter of 2024. Gross margin expanded to 63%, driven by favorable product mix and operating leverage. Commercial Channel revenue increased 22% year over year driven by timing of 2025 shipments to international customers and growth in the Integrity™ Implant System, while OEM Channel revenue declined 12%, reflecting anticipated U.S. OA Pain Management pricing dynamics.","length":459,"tagName":"p"},{"type":"text","content":"For the full year 2025, total revenue was $112.8 million, a decrease of 6% compared to 2024, in line with expectations. Commercial Channel revenue increased 15% year over year, supported by continued Integrity growth and international OA Pain Management performance. OEM Channel revenue declined 17% for the year driven by lower Monovisc® an...